You are here

Therapeutic Advances in Medical Oncology
Share

Therapeutic Advances in Medical Oncology

2016 Impact Factor: 6.294
2016 Ranking: 28/217 in Oncology
Source: 2016 Journal Citation Reports® (Clarivate Analytics, 2017); Indexed in PubMed Central

Managing Editor
Georgia Patey SAGE Publications Ltd, UK
Associate Editors
Tanya B. Dorff USC Keck School of Medicine, Los Angeles, CA, USA
Axel Grothey Mayo Clinic, Rochester, MN, USA
Sara Hurvitz University of California, Los Angeles, CA, USA
Jonathan Ledermann UCL Cancer Institute, London, UK
Karl Lewis University of Colorado Denver, USA
Antonio Rossi IRCCS Casa Sollievo della Sofferenza, Italy


eISSN: 17588359 | ISSN: 17588340 | Current volume: 9 | Current issue: 10 Frequency: Monthly

Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of oncology. The journal can be accessed online without charge at http://journals.sagepub.com/home/tam.

The journal is a member of the Committee on Publication Ethics (COPE).

All articles are listed on PubMed.

For manuscripts submitted to Therapeutic Advances in Medical Oncology, an article fee of 2,000 USD/1,335 GBP (+VAT where applicable*) will apply, payable upon acceptance. These articles will be published under a Creative Commons Licence and will be made openly available.

*If the paying author/institution is based in the European Union, to comply with European law, Value Added Tax (VAT) must be added to the article fee. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions. VAT invoices will be issued in GBP.

Please direct any enquiries to oncology@saegpub.co.uk.

For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

Commercial Sales Team, London, UK

Tel: +44 20 7336 1205

Email: reprints@sagepub.co.uk




Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The editors welcome original research articles across all areas of oncology.

The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission and Online First publication is usually within 3 weeks of Acceptance.

Editorial Board
Dirk Arnold José de Mello Saúde, Carnaxide, Portugal
Carlos L Arteaga Vanderbilt University, Nashville, TN, USA
Christopher Benz Buck Institute for Age Research, Novato, CA, USA
Michael Boyer University of Sydney, Sydney, Australia
Kim N Chi University of British Columbia, Vancouver, BC, Canada
Toni K Choueiri Dana-Farber Cancer Institute, Boston, MA, USA
Ronald de Wit Erasmus University Rotterdam, Rotterdam, Netherlands
Wilfried Eberhardt University Duisburg-Essen, Essen, Germany
Tim Eisen Cambridge University, Cambridge, UK
Alfredo Falcone University of Pisa, Livorno, Italy
Michael Findlay University of Auckland, Auckland, New Zealand
Jorge A. Garcia Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
Cesare Gridelli S.G. Moscati Hospital, Avellino, Italy
Nasser H. Hanna Indiana University - Purdue University, Indianapolis, IN, USA
Paul R Helft Indiana University School of Medicine, Indianapolis, IN, USA
Maha Hussain Northwestern University Lurie Cancer Center, Chicago, IL, USA
David H Ilson Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Sung-Bae Kim University of Ulsan, South Korea
Ragini Kudchadkar Emory University School of Medicine, Atlanta, GA, USA
James Larkin Royal Marsden Hospital, London, UK
Robert R McWilliams Mayo Clinic, Rochester, MN, USA
Sofia Merajver University of Michigan, Ann Arbour, MI, USA
Mark Middleton Oxford University, Oxford, UK
Paul Nathan Mount Vernon Cancer Centre, Northwood, UK
Sylvie Negrier Centre Léeon-Béerard, Lyon, France
Harvey I Pass New York University, New York, NY, USA
Edith A Perez Mayo Clinic, Jacsonville, FL, USA
Robert Pirker Medical University of Vienna, Vienna, Austria
Emilio Porfiri Birmingham University, Birmingham, UK
David Quinn University of Southern California, Los Angeles, CA, USA
Joseph D Rosenblatt University of Miami, Miami, FL, USA
Frances Shepherd Princess Margaret Hospital, Toronto, ON, Canada
Josep Tabernero Vall d'Hebron University Hospital, Barcelona, Spain
Scott Tagawa Weill Cornell Medicine, New York, NY, USA
Toni Wozniak Wayne State University, Detroit, MI, USA
Andrew X Zhu Massachusetts General Hospital Cancer Center, Boston, MA, USA
  • Chemical Abstracts Service (CAS)
  • Clarivate Analytics: Science Citation Index Expanded (SCIE)
  • Medscape
  • PubMed
  • SCOPUS
  • Manuscript Submission Guidelines: Therapeutic Advances in Medical Oncology 

    1. Open Access
    2. Article fee
    3. Article Types
    4. Editorial policies
      4.1 Peer Review Policy
      4.2 Authorship
      4.3 Acknowledgements
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical Trials
      4.8 Reporting guidelines
      4.9 Data
    5. Publishing policies
      5.1 Publication ethics
      5.2 Contributor's publishing agreement
    6. Preparing your manuscript
      6.1 Word processing formats
      6.2 Artwork, figures and other graphics
      6.3 Supplementary material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting your manuscript
      7.1 ORCID
      7.2 Information required for completing your submission
      7.3 Corresponding author contact details
      7.4 Permissions
    8. On acceptance and publication
      8.1 SAGE Production
      8.2 Continuous publication
      8.3 Promoting your article
    9. Further information

    This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the journal’s submission site http://mc.manuscriptcentral.com/tao to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Medical Oncology will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    1. Open Access

    Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

    For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.

    Back to top

    2. Article fee

    Unsolicited manuscripts submitted to Therapeutic Advances in Medical Oncology are subject to an article fee of 2,000 USD (+VAT where applicable*) payable upon acceptance. These articles will be published under a Creative Commons Licence and will be made openly available.

    *If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.

    Back to top

    3. Article types

    Therapeutic Advances in Medical Oncology considers the following kinds of article for publication:

    1. Original Articles. The Editors will consider preclinical, interventional and observational studies with clearly stated aims, well-reported methodology (including main outcome measures) and results, and a discussion of the results in the context of the published literature).
    2. Review Articles. These manuscripts are usually commissioned by the Editors, but the following types of high-quality review will be considered:
      (a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal;
      (b) Perspective reviews – review articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic; 
      (c) Drug reviews – review articles focusing on the available evidence for the use of a particular drug or combination therapy.
    3. Systematic Reviews. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8).
    4. Meta-analyses. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8).
    5. Case Reports. These structured reports should describe an unusual case and include a full review of the pertinent literature and a section on implications for clinical care.
    6. Case Series. These descriptive structured reports (which do not involve formal hypotheses or pre-specified methodology or analyses) of a small group of patients should include a full review of the pertinent literature and a section on implications for clinical care.
    7. Study Protocols. These can be for forthcoming or ongoing research. Information on trial registration (where applicable) and ethics approval should be included in the manuscript.
    8. Letters to the Editor. These brief opinion pieces should be as concise as possible, usually no more than 1000 words.

    The journal considers the results of rigorous, well-designed studies that demonstrate “no effect” or that fail to replicate previous work (“negative data”) as important to the advancement of science. Therapeutic Advances in Medical Oncology welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.

    Back to top

    4. Editorial policies

    4.1 Peer review policy

    The journal's policy is to obtain at least two independent reviews of each article. Therapeutic Advances in Medical Oncology operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author.  Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations.  All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.

    As part of the submission process you will be asked to provide the names of 3 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:

      • The reviewer should have no prior knowledge of your submission
      • The reviewer should not have recently collaborated with any of the authors 
      • Reviewer nominees from the same institution as any of the authors are not permitted

    You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

    Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

      1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
      2. Drafted the article or revised it critically for important intellectual content,
      3. Approved the version to be published,
      4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    4.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.

    It is not necessary to disclose use of language polishing services.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    4.4 Funding

    Therapeutic Advances in Medical Oncology requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    4.5 Declaration of conflicting interests

    It is the policy of Therapeutic Advances in Medical Oncology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    For guidance on conflict of interest statements, please see the ICMJE recommendations.

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.

    4.7 Clinical trials

    Therapeutic Advances in Medical Oncology endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    4.9 Data

    SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.

    Therapeutic Advances in Medical Oncology encourages all authors to submit any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at oncology@sagepub.co.uk

    Back to top

    5. Publishing policies

    5.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

    5.1.1 Plagiarism

    Therapeutic Advances in Medical Oncology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    5.1.2 Prior publication

    If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    5.2 Contributor's publishing agreement

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement.  Therapeutic Advances in Medical Oncology publishes manuscripts under Creative Commons licenses. The standard  license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.

    Alternative license arrangements are available, for example to meet particular funder mandates, made at the author’s request.

    Back to top

    6. Preparing your manuscript

    6.1 Word processing formats

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    6.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines  

    Figures supplied in color will appear in color online.

    6.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.

    6.4 Reference style

    Therapeutic Advances in Medical Oncology adheres to the SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.

    If you use EndNote or Zotero to manage references, you can download the appropriate output style file to help format your references quickly.

    EndNote: here 
    Zotero: here

    6.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    7. Submitting your manuscript

    Therapeutic Advances in Medical Oncology is hosted on SAGE Track, a web-based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/tao to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    7.1 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.

    We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.

    7.2 Informtion required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    7.3 Corresponding author contact details

    Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

    7.4 Permissions

    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway

    Back to top

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been sent to SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.

    8.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.

    8.2 Online publication

    One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.

    8.3 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos

    Back to top

    9. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Therapeutic Advances in Medical Oncology editorial office as follows:

    oncology@sagepub.co.uk

    For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

    Commercial Sales Team, London, UK Tel: +44 20 7336 1205 Email: reprints@sagepub.co.uk

    [Return to top]

    Back to top